Comparative Pharmacology
Head-to-head clinical analysis: FAVLYXA versus FUZEON.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FAVLYXA versus FUZEON.
FAVLYXA vs FUZEON
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Acyclic nucleoside phosphonate prodrug that inhibits viral RNA-dependent RNA polymerase (RdRP) by competing with adenosine triphosphate (ATP). It incorporates into nascent viral RNA causing chain termination after incorporation of the first 1-2 nucleotides.
Fusion inhibitor; binds to gp41 of HIV-1, preventing conformational changes required for fusion with host CD4+ T-cell membrane.
200 mg orally twice daily for 10 days.
90 mg subcutaneously twice daily
None Documented
None Documented
Terminal elimination half-life approximately 5-7 hours in patients with normal renal function; prolonged in renal impairment (up to 24 hours in severe impairment).
Terminal elimination half-life: 3.8 hours; clinically, steady-state plasma concentrations are achieved within 2-3 days with subcutaneous administration
Primarily renal excretion of unchanged drug (approx. 85%) with biliary/fecal elimination accounting for the remainder (approx. 15%).
Renal: approximately 70% as unchanged drug via glomerular filtration; fecal: <5% as metabolites
Category C
Category C
Antiviral
Antiviral